Follow Healthline   |   Healthline on TwitterTwitter   |   Healthline on FacebookFacebook
Symptom Search   |   Treatment Search   |   Doctor Search   |   Drug Search

Hemophilia A : Drugs

Healthline Premium Tools

Advertisement
Marketplace

Specific Drugs Articles

factor viia (recombinant)
Biosynthetic preparation (recombinant DNA origin) of blood coagulation factor VIIa.
Source:AHFS
Factor VIIa (Recomb)(Murine)(Bovine)(Hamster) Sol...
FACTOR VIIa, RECOMBINANT (fak tir VIIa, ree kom bi nant) helps to prevent or control bleeding in patients with hemophilia A or hemophilia B who have clotting factor inhibitors. This medicine may also be used to treat bleeding in patients with factor VII deficiency or in select patients who have other types of bleeding problems. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
Source:GOLD
antihemophilic factor (human)
Preparation of antihemophilic factor (blood coagulation factor VIII) prepared from pooled human plasma from suitable whole-blood donors.
Source:AHFS
Desmopressin Acetate Solution for injection
DESMOPRESSIN (des moe PRESS in) is a man made hormone. It is used to treat or prevent bleeding in patients with Hemophilia A and von Willebrand's Disease. This medicine is also used to reduce urine production in patients with diabetes insipidus. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
Source:GOLD
Desmopressin Acetate Oral tablet
DESMOPRESSIN (des moe PRESS in) is a man made form of the hormone vasopressin. It helps to reduce frequent urination and excessive thirst. This medicine is used to treat central diabetes insipidus and bed wetting. It is also used in patients after a head injury or certain brain surgeries. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
Source:GOLD
desmopressin
Synthetic polypeptide analog of arginine vasopressin (antidiuretic hormone [ADH]); reduces urinary output and plasma osmolality and increases urine osmolality, as well as dose-dependent increases in plasma factor VIII (antihemophilic factor), plasminogen activator, and, to a lesser degree, factor VIII-related antigen and ristocetin cofactor activities.
Source:AHFS
Advertisement
Back to Top